Zhen Chen

Also affiliated with Cancer Institute (WIA), Piedmont Cancer Institute, First Affiliated Hospital of Hunan University of Traditional Chinese Medicine, Winship Cancer Institute

MedicineBiochemistry, Genetics and Molecular Biology

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 10 papers. Top paper: “Targeting MKK3/c-Myc interaction to overcome osimertinib acquired resistance in EGFR mutant lung cancer”.

Targeting MKK3/c-Myc interaction to overcome osimertinib acquired resistance in EGFR mutant lung cancer

Cancer Letters(2025)10.1016/j.canlet.2025.218010

N/A

0.208DataRank · unranked

3 citations

Karin A. Vallega, Dongsheng Wang, Elsa Bildtsen, Haian Fu, Suresh S. Ramalingam +3 more

Targeting c-Myc to Overcome Acquired Resistance of EGFR Mutant NSCLC Cells to the Third-Generation EGFR Tyrosine Kinase Inhibitor, Osimertinib

Cancer Research(2021)10.1158/0008-5472.can-21-0556

N/A

0DataRank · unranked

67 citations

Zhen Chen, Hongjing Zang, Songqing Fan, Jiajia Gu, Guojing Zhang +7 more

Membrane-Associated RING-CH 8 Functions as a Novel PD-L1 E3 Ligase to Mediate PD-L1 Degradation Induced by EGFR Inhibitors

Molecular Cancer Research(2021)10.1158/1541-7786.mcr-21-0147

N/A

0DataRank · unranked

43 citations

Jianping Guo, Karin A. Vallega, C. Hu, Zhen Chen, Yunfu Deng +7 more

Top-down feedback enables flexible coding strategies in olfactory cortex

bioRxiv (Cold Spring Harbor Laboratory)(2021)10.1101/2021.08.06.455459

N/A

0DataRank · unranked

0 citations

Krishnan Padmanabhan, Zhen Chen

Data from Targeting c-Myc to Overcome Acquired Resistance of EGFR Mutant NSCLC Cells to the Third-Generation EGFR Tyrosine Kinase Inhibitor, Osimertinib

(2023)10.1158/0008-5472.c.6513256.v1

N/A

0DataRank · unranked

0 citations

Zhen Chen, Hongjing Zang, Songqing Fan, Jiajia Gu, Guojing Zhang +7 more

The novel MET inhibitor, HQP8361, possesses single agent activity and enhances therapeutic efficacy of osimertinib, against NSCLC cells with acquired resistance to osimertinib due to MET amplification

Research Square (Research Square)(2020)10.21203/rs.3.rs-25317/v1

N/A

0DataRank · unranked

1 citations

Yiting Li, Kevin D.-Y. Sun, Jiajia Gu, Zhen Chen, Taofeek K Omonikoko +3 more

Inhibition of hTERT/telomerase/telomere mediates therapeutic efficacy of osimertinib in EGFR mutant lung cancer

The Journal of Experimental Medicine(2024)10.1084/jem.20240435

N/A

0DataRank · unranked

15 citations

Karin A. Vallega, Dongsheng Wang, Zihan Quan, Songqing Fan, Qiming Wang +4 more

Targeting Transient Receptor Potential Melastatin‐2 (TRPM2) Enhances Therapeutic Efficacy of Third Generation EGFR Inhibitors against EGFR Mutant Lung Cancer

Advanced Science(2024)10.1002/advs.202310126

N/A

0DataRank · unranked

10 citations

Karin A. Vallega, Vijay K. Boda, Zihan Quan, Dongsheng Wang, Songqing Fan +5 more

The natural product berberine synergizes with osimertinib preferentially against MET-amplified osimertinib-resistant lung cancer via MET inhibition

(2024)10.22541/au.170668621.16410191/v1

N/A

0DataRank · unranked

1 citations

Karin A. Vallega, Haiying Chen, Jia Zhou, Shi‐Yong Sun, Zhen Chen

DNA topoisomerase II inhibition potentiates osimertinib’s therapeutic efficacy in EGFR-mutant non–small cell lung cancer models

Journal of Clinical Investigation(2024)10.1172/jci172716

N/A

0DataRank · unranked

30 citations

Karin A. Vallega, Dongsheng Wang, Zihan Quan, Songqing Fan, Qiming Wang +4 more